The Journal of Urology · 2017 · 152 citations · 21 references
MedicinePathologyUrologyDiagnostic ImagingGenitourinary OncologyProstate DiseaseProstate BiopsyProstate CancerProstate ImagingProstate PathologyTransrectal UltrasonographyUrologic Cancer DiagnosisClinically Significant Prostate Cancer DetectionMagnetic Resonance Imaging Fusion BiopsyMultiparametric ImagingMultiparametric Prostate Magnetic Resonance ImagingProstate Cancer DiagnosisSystematic BiopsySystematic Prostate BiopsyT2-weighted Imaging
PURPOSE: The PI-RADS™ (Prostate Imaging Reporting and Data System), version 2 scoring system, introduced in 2015, is based on expert consensus. In the same time frame ISUP (International Society of Urological Pathology) introduced a new pathological scoring system for prostate cancer. Our goal was to prospectively evaluate the cancer detection rates for each PI-RADS, version 2 category and compare them to ISUP group scores in patients undergoing systematic biopsy and magnetic resonance imaging-transrectal ultrasound fusion guided biopsy. MATERIALS AND METHODS: A total of 339 treatment naïve patients prospectively underwent multiparametric magnetic resonance imaging evaluated with PI-RADS, version 2 with subsequent systematic and fusion guided biopsy from May 2015 to May 2016. ISUP scores were applied to pathological specimens. An ISUP score of 2 or greater (ie Gleason 3 + 4 or greater) was defined as clinically significant prostate cancer. Cancer detection rates were determined for each PI-RADS, version 2 category as well as for the T2 weighted PI-RADS, version 2 categories in the peripheral zone. RESULTS: The cancer detection rate for PI-RADS, version 2 categories 1, 2, 3, 4 and 5 was 25%, 20.2%, 24.8%, 39.1% and 86.9% for all prostate cancer, and 0%, 9.6%, 12%, 22.1% and 72.4% for clinically significant prostate cancer, respectively. On T2-weighted magnetic resonance imaging the cancer detection rate in the peripheral zone was significantly higher for PI-RADS, version 2 category 4 than for overall PI-RADS, version 2 category 4 in the peripheral zone (all prostate cancer 36.6% vs 48.1%, p = 0.001, and clinically significant prostate cancer 22.9% vs 32.6%, p = 0.002). CONCLUSIONS: The cancer detection rate increases with higher PI-RADS, version 2 categories.
21
Cancer treatment and survivorship statistics, 2016
Kimberly D. Miller, Rebecca L. Siegel, Chun Chieh Lin et al. · CA A Cancer Journal for Clinicians · 2016 · 6.2K citations · Full text
Jonathan I. Epstein, Zhaoyong Feng, Bruce J. Trock et al. · European Urology · 2012 · 666 citations